Drug-induced autoimmunity

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 547-551

  Dedeoglu, Fatma ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Autoantibodies; Drug metabolites; Drug induced lupus; Drug induced vasculitis; Hypomethylation; Tumor necrosis factor antagonists

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; HISTONE ANTIBODY; HYDRALAZINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SULFADIAZINE; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DRUG ERUPTION; DRUG INDUCED DISEASE; HUMAN; LUPUS LIKE SYNDROME; MACULOPAPULAR RASH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HLA ANTIGENS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 69549117354     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832f13db     Document Type: Review

References (38)

1. Mongey AB, Hess EV. Drug insight: autoimmune effects of medications - what's new? Nat Clin Pract Rheumatol 2008; 4:136-144. A comprehensive review of DIA with emphasis on the types of autoantibodies with expanding spectrum, clinical features, discordance between the development of autoantibodies and clinical autoimmunity and hypotheses on the mechanisms. It lists all the reported drugs in association with autoimmune features.
2. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301:99-105.
3. Mor A, Pillinger MH, Wortmann RL, Mitnick HJ. Drug-induced arthritic and connective tissue disorders. Semin Arthritis Rheum 2008; 38:249-264. An extensive review of the literature for drug-induced rheumatologic conditions between 1987 and 2006 expanding to vaccines, herbal medicines and radiocontrast agents.
4. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20:35-39. A concise review of DIA with emphasis on vasculitic features and antineutrophil cytoplasmic antibodies.
5. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006; 18:96-100. (Pubitemid 43740411)
6. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86:242-251. (Pubitemid 47067483)
7. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108:166-182.
8. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007; 34:380-385. (Pubitemid 46255759)
9. Wendling D, Balblanc JC, Briancon D, et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008; 75:315-318.
10. Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156:329-336. (Pubitemid 46095962)
11. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156:486-491. (Pubitemid 46253946)
12. Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol 2008; 27:377-380. A comprehensive report of 12 patients who developed psoriatic lesions while on TNF antagonists. It also mentions possible mechanisms of the pathogenesis.
13. Suess A, Sticherling M. Leflunomide in subacute cutaneous lupus erythematosus: two sides of a coin. Int J Dermatol 2008; 47:83-86.
14. Marzano AV, Ramoni S, Del Papa N, et al. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 2008; 17:329-331. (Pubitemid 351655801)
15. Nelson MR, Bacanu SA, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2009; 9:23-33. This study explains the available techniques to identify genetic basis of adverse drug reactions and monitoring.
16. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet 2008; 17:R174-R179.
17. Jorgensen A, Alfirevic A. Pharmacogenetics and pharmacogenomics: adverse drug reactions. Pharmacogenomics 2008; 9:1397-1401.
18. El-Hallak M, Giani T, Yeniay BS, et al. Chronic minocycline-induced autoimmunity in children. J Pediatr 2008; 153:314-319. This study draws attention to potential chronicity of the MIA, and it is the largest series involving children.
19. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am J Clin Dermatol 2003; 4:407-428.
20. Margolis DJ, Hoffstad O, Bilker W. Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157:540-546. (Pubitemid 47256131)
21. Brogan BL, Olsen NJ. Drug-induced rheumatic syndromes. Curr Opin Rheumatol 2003; 15:76-80.
22. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65-70. A systematic review of published literature on drug-induced SCLE. It appears that drugs used in cardiovascular diseases are more commonly involved, and anti-Ro/ SS-A antibody is the most common autoantibody present in these patients.
23. Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review. J Cutan Pathol 2003; 30:161-173.
24. Hautmann G, Campanile G, Lotti TM. The many faces of cutaneous vasculitis. Clin Dermatol 1999; 17:515-531.
25. Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum 2006; 36:4-9. (Pubitemid 44144499)
26. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006; 142:198-202. (Pubitemid 43276531)
27. Hu S, Cohen D, Murphy G, et al. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis 2008; 81:336-338.
28. Beasley R, Bibby S, Weatherall M. Leukotriene receptor antagonist therapy and Churg-Strauss syndrome: culprit or innocent bystander? Thorax 2008; 63:847-849. This editorial nicely summarizes the available recent data on the possible association of leukotriene inhibitors and development of CSS.
29. Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax 2008; 63:677-682.
30. Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883-888.
31. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by antitumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7:R545-R551.
32. Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a twoyear prospective study. Arthritis Res Ther 2004; 6:R535-R543.
33. Rubin RL. Drug-induced lupus. Toxicology 2005; 209:135-147.
34. Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18:677-688.
35. Mazari L, Ouarzane M, Zouali M. Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc Natl Acad Sci U S A 2007; 104:6317-6322. (Pubitemid 47186092)
36. Gorelik G, Fang JY, Wu A, et al. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazineinduced lupus. J Immunol 2007; 179:5553-5563.
37. Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and druginduced lupus patients. Autoimmun Rev 2008; 7:376-383. A nice review of the effects of degree of methylation on various immune functions.
38. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol 2007; 56:S114-S116. (Pubitemid 46552083)